Inserm is the only public research organization in France entirely dedicated to health.
Our objective: to promote the health of all by advancing knowledge on living organisms and their diseases, and by developing innovation.
• Address major biomedical research challenges

• Take action to improve the health of all

• Disseminate knowledge for the benefit of all
Address major biomedical research challenges
Address major biomedical research challenges

Be a reference in biomedical research

In Europe and worldwide

- 7,000 international cooperation agreements with 106 countries
- 66 European and international partner laboratories
- 35 institutional cooperation agreements

In France

- 278 research units
- 34 clinical investigation centers
- 48 service units

15,234 staff

- 4,972 civil servants (2,180 researchers, ATIP-Avenir contracts included)
- 3,719 contract staff and temporary workers (incl. ATIP-Avenir contracts)
  > 50 ATIP-Avenir contracts
- 6,534 teacher-researchers and hospital teachers

A budget of €1,119 million

- €707 million from government subsidies
- €412 million from internal resources

Patents and licenses

- A portfolio of 2,492 patent families
- 131 new license agreements signed
- 306 R&D partnerships
Address major biomedical research challenges

Be a reference in biomedical research (2)

In Europe
- No. 1 academic applicant in the biomedical sector in Europe
- No. 2 European applicant in the biotechnology sector
- No. 5 European applicant in the pharmaceutical sector

Horizon Europe launch and 2021 results:
- ERC: 57 projects, 2nd French ERC grant winner
- Marie Skłodowska Curie Actions: 9 individual grants, 11 doctoral networks, including 2 coordinations
- Health Cluster: 54 projects, including 13 coordinations
- EIC: 16 projects, including 2 coordination
- Infrastructure: participation in 6 projects

Horizon 2020 results:
- 1st coordinator of the Health societal challenge
- 396 contracts, incl. 83 grant winners and 53 Marie Skłodowska-Curie grants

Close dialogue
with over 500 patient organizations for
- participatory research
- meetings and debates between patients and researchers

10,976 original articles
(publications 2022)
Address major biomedical research challenges

Make changes to adapt

1964
Inserm is created

1983
Public scientific and technological institute, entirely dedicated to human health and biomedical research
Placed under the joint authority of the French Ministries of Health and Research

2009
Inserm, following reform, ensures the strategic, scientific and operational coordination of biomedical research

Aviesan, the French National Alliance for Life Sciences and Health, is created

2011

2014
Inserm establishes its 2021-2025 Objectives, resources and performance contract

2019
Inserm establishes its 2025 Strategic plan with the French State

2022
Inserm celebrates its 50th anniversary

2025
Inserm establishes its 2025 Strategic plan with the French State
Our organization

Thematic institutes
- Cancer
- Cell biology, development and evolution
- Genetics, genomics and bioinformatics
- Health Technologies
- Immunology, inflammation, infectious diseases and microbiology
- Molecular and structural basis of living organisms
- Neurosciences, cognitive sciences, neurology, psychiatry
- Pathophysiology, metabolism, nutrition
- Public health

Divisions
- Communication
- Financial Affairs
- Human Resources
- Information Systems
- Legal Affairs
- National and Foreign Affairs
- Open Science
- Program Assessment
- Strategic Program
- Accounting Department

Regional Offices
- Auvergne-Rhône-Alpes
- Est
- Grand Ouest
- Île-de-France (4)
- Nord-Ouest
- Nouvelle-Aquitaine
- Occitanie Méditerranée
- Occitanie Pyrénées
- Provence-Alpes-Côte d’Azur and Corsica

Address major biomedical research challenges
Address major biomedical research challenges

Our presence in France

278 research units
48 service units
34 clinical investigation centers
Our presence in France (2)

- Address major biomedical research challenges

85% of Inserm
Strengths in...

14 research universities, in which Inserm invests more than €10M each year
Our main partners in France and abroad

- **37** universities
- A key partner of **14** research universities in which Inserm invests more than €10M each year
- On **14** Idex and I-sites, Inserm invests **72%** of its resources
- Research units in **31** teaching hospitals

- National research institutions: CNRS / Inrae / Inria / IRD / INED…
- French top graduate schools: ENS, ESPCI, EHESS, École polytechnique, EHESP, École des Mines, ENVA…
- Industry: Astra Zeneca/MedImmune, MSD Avenir, Sanofi, AdBio Partners…
- Foundations and associations: Fondation Bettencourt Schueller, FRM…
- European and international academic institutions: Helmholtz, NIH…
• Address major biomedical research challenges

Our partner laboratories in Europe

• Inserm research teams launch many informal scientific collaborations with European laboratories.

• In addition to these spontaneous cooperation networks, Inserm signed, in 2024, 40 partnership agreements in Europe thanks to dedicated instruments: thematic coordination programs, international research projects and first step projects.
Address major biomedical research challenges

Our partner laboratories abroad

- Inserm research teams launch many informal scientific collaborations with European laboratories.

- In addition to these spontaneous cooperation networks, Inserm signed, in 2024, 85 partnership agreements worldwide thanks to dedicated instruments: thematic coordination programs, international research projects and first step projects.

- Besides, Inserm is working with 11 partner countries through ANRS MIE.
Take action to improve the health of all
Take action to improve the health of all

Our missions for health

- Produce and disseminate knowledge nationally and internationally
- Play a major role in the national coordination of health research
- Support higher education and research training
- Initiate, develop and coordinate biomedical research of excellence
- Provide scientific expertise and support for science based policy in health
- Create value from discoveries and their applications
Take action to improve the health of all

Our fields of activity and expertise

- Fundamental research
- Clinical and preclinical trials
- Cohorts and epidemiological studies
- Provision of expertise and contribution to public health and research policy
- Biomedical research infrastructure
- Technology transfer
Cohorts and epidemiological studies

Over 1.6 million people
(2% of the French population) participating in Inserm cohorts

EpiCOV
130,000 volunteers for research on SARS-CoV-2

ELFE
20,000 children born in 2011, longitudinal study from birth to adult age

Constances
220,000 subjects representative of the French population, aged 18 to 69 years on inclusion + a biobank of 100,000 subjects

RaDiCo
over 5,000 people with rare diseases in 12 cohorts

Major public health expertise and research databases, accessible online

Epidemiologie-France portal
French health database catalogue
> epidemiologie-france.aviesan.fr

CépiDc
Epidemiology center on the medical causes of death
> cepidc.inserm.fr

Orphanet
Portal for rare diseases and orphan drugs
> orpha.net

* Take action to improve the health of all
A continuum from basic to clinical, therapeutic, and public health research

- Basic research
- Preclinical Studies
  - Proof of concept
- Phases I, IIa, IIb, III
- Phase IV

- 278 research units
- National research infrastructures
- 34 clinical research centers
- About 90 cohorts & large scale studies
• Take action to improve the health of all

Value creation activities which are bearing fruit

- 2,492 patent family’s portfolio
- 152 new patent families in 2023
- An annual budget of €1.8 M to fund project maturation or proof of concept
- A maturation budget reaching €25.1 M invested in 419 projects since 2009
- €550.2 M industrial partnerships since 2010 (patents, research contracts)

- ~ €25-30 M per year from licensing agreements
- Over 400 technologies and research tools available for licensing
- Strategic alliances with MSD Avenir, AstraZeneca/MedImmune, Sanofi, AdBio Partners…
- 10 startups created each year via Inserm Transfert (Inserm’s subsidiary)
- Partnerships with SATTs
Take action to improve the health of all

Inserm & Inserm Transfert in EPO rankings

- No. 5 European applicant in the pharmaceutical sector
- No. 2 European applicant in the biotechnology sector (5th year)
- No. 1 European research academic institution in the biomedical sector
- 2,492 patent families as of 31/12/2023
• Take action to improve the health of all

Inserm Transfert: partnering with industries

Some of our industrial partners: privileged partner of major industrials, mid-size, SME, involved in human health, at the international level

Roche  MedImmune  Baxter  Fresenius  Janssen
ultragenyx  Tri  AstraZeneca  dbv  Johnson & Johnson Innovation
Lilly
Sanofi  Quest Diagnostics  Iliad  Boehringer Ingelheim  GSK
Gilead
Qiagen  Bristol Myers Squibb  MSD  Lilly
Abbvie  Otsuka
• Take action to improve the health of all

Inserm spin-offs based on inventors as drivers
Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- the first prenatal diagnostic tests;
- understanding the HLA system and the ensuing immune reactions;
- the first in vitro fertilization;
- radiotherapy for cancer;
- the first skin graft;
- deep brain stimulation in the treatment of Parkinson’s disease;
- gene therapy in the treatment many diseases;
- innovative technologies like bioprinting, ultrasound, imaging organoids…
Disseminate knowledge for the benefit of all
Since 1999, Inserm ethics committee has focused on ethical questions in emerging areas of medical innovation

- Publication of multiples notes on genome editing and participation in the creation of ARRIGE (Association for Responsible Research and Innovation in Genome Editing) in 2018
- Launch in 2022 of Volrethics to define common international ethical rules to protect healthy volunteers in biomedical research
- Think tanks on gender and health research, research on the human embryo, genomic medicine, neurotechnology in education, organoids and organs on chips...
Collective expert reviews and contribution to public health policy

Inserm fulfills its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.
Our work with patient organizations

Towards research in partnership with patient organizations and civil society collectives

• Promote meetings and direct dialogue between researchers and collectives
• Act for the structuring, coordination and animation of participatory research projects
• Help to better take into account these projects in the assessment of researchers and structures
• Facilitate access to scientific information for society
Our presence in the service of public information

- Disseminate knowledge for the benefit of all

**inserm.fr**
- 9,600,000 visits
- 154,000 followers
- 160,000 followers
- 52,000 followers
- 17,000 followers
- 397,000 subscribers

**Live lectures and 30’ Santé broadcast**
- 166,500 views

**Public events**
- 2.8 million participants and views

**Meetings on participatory research**
- 250 participants*

**Canal Détox information videos and articles**
- 273,000 views

* 2022 figures
#FromScienceToHealth